Clinically significant interactions with drugs used in the treatment of tuberculosis

Drug Safety

Volumn 25, Issue 2, 2002, Pages 111-113

  Yew, W W ^a  

^a GRANTHAM HOSPITAL   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIINFECTIVE AGENT; BENZODIAZEPINE DERIVATIVE; CARDIOVASCULAR AGENT; CONTRACEPTIVE AGENT; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; FLUOXETINE; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; INDINAVIR; ISONIAZID; ITRACONAZOLE; KETOCONAZOLE; METAL ION; PARACETAMOL; PROTEINASE INHIBITOR; PSYCHOTROPIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SERTRALINE; SULFONYLUREA DERIVATIVE; THEOPHYLLINE DERIVATIVE; TUBERCULOSTATIC AGENT; UNINDEXED DRUG;

BIOTRANSFORMATION; COMBINATION CHEMOTHERAPY; COMORBIDITY; DISEASE ASSOCIATION; DRUG CROSS REACTIVITY; DRUG METABOLISM; DRUG MONITORING; ENZYME BINDING; ENZYME INHIBITOR INTERACTION; FOOD DRUG INTERACTION; GERIATRIC DISORDER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; INTESTINE ABSORPTION; LIVER METABOLISM; METAL BINDING; POLYPHARMACY; PRIORITY JOURNAL; PROTEINASE INHIBITION; REVIEW; TUBERCULOSIS;

EID: 0036196202     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200225020-00005     Document Type: Review

References (297)

1. Global burden of tuberculosis: Estimated incidence, prevalence and mortality by country
2. The association of age with the presentation and outcome of tuberculosis: A five-year survey
3. Tuberculosis in the elderly
4. Clinically significant drug interactions with anti-tuberculosis agents
5. Therapeutic implications of drug interactions in the treatment of human immunodeficiency virus-related tuberculosis
6. Plasma protein binding displacement interactions: Why are they still regarded as clinically important?
7. Clinical and toxicological consequences of the inductive potential of ethanol
8. Drug interactions with tobacco smoking: An update
9. Isoniazid induced encephalopathy in dialysis patients
10. Update on rifampin drug interactions
11. Update on rifampin drug interactions II
12. Update on rifampin drug interactions III
13. Management of drug interactions in patients with HIV
14. Tuberculosis and the elderly: A community health perspective
15. Mycobacterial infections in the transplant patient
16. Newer antidepressants and the cytochrome P450 system
17. Relevance of induction of human drug-metabolizing enzymes: Pharmacological and toxicological implications
18. Prediction of pharmacokinetic alterations caused by drug-drug interactions: Metabolic interaction in the liver
19. Inhibition and induction of cytochrome P450 and the clinical implications
20. Inhibition and induction of human cytochrome P450 (CYP) enzymes
21. Induction of drug metabolizing enzymes: Pharmacokinetic and toxicological consequences in humans
22. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition
23. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions
24. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants
25. Homozygous disruption of the murine mdr P-glycoprotein gene leads to a complete absence of phospholipid from bile to liver disease
26. Tissue distribution of the human MDR3 P-glycoprotein
27. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein
28. P-glycoprotein: A major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans
29. Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: A new type of drug/drug interaction
30. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin
31. Clinical pharmacokinetics of antituberculosis drugs
32. Serum concentrations and half-life of rifampicin after simultaneous oral administration of aminosalicylic acid or isoniazid
33. Effect of pyrazinamide on rifampicin kinetics in patients with tuberculosis
34. Isoniazid and ethionamide serum levels in Finnish subjects
35. Drug combinations and the bioavailability of rifampicin
36. The promise and reality of fixed dose combinations with rifampicin
37. Assessing bioavailability of fixed-dose combinations of anti-tuberculosis medications
38. Rifampicin bioavailability: A review of its pharmacology and the chemotherapeutic necessity for ensuring optimal absorption
39. Toxic hepatitis with isoniazid and rifampin: A meta-analysis
40. Rifampin-induced release of hydrazine from isoniazid: A possible cause of hepatitis during treatment of tuberculosis with regimens containing isoniazid and rifampin
41. Risk factors for hepatotoxicity from anti-tuberculosis drugs: A case-control study
42. A comparison of two regimens for the treatment of Mycobacteirum avium complex bacteremia in AIDS: Rifabutin, ethambutol and clarithromycin versus rifampin, ethambutol, clofazimine and ciprofloxacin
43. Drug-drug interactions of clinical significance in the treatment of patients with Mycobacterium avium complex disease
44. The clinical pharmacokinetics of rifabutin
45. Isoniazid drug and food interactions
46. Outbreak of unexpected reactions among epileptics taking isoniazid
47. Depression of parahydroxylation of diphenylhydantoin by antituberculosis chemotherapy
48. Inhibition of diphenylhydantoin metabolism in rats and in rat liver microsomes by antitubercular drugs
49. Diphenylhydantoin intoxication: A complication of isoniazid therapy
50. Clinical importance of the interaction of phenytoin and isoniazid
51. Death due to isoniazid and phenytoin
52. Phenytoin toxicity in a patient with isonaizid-induced hepatitis
53. Influence of rifampicin and isoniazid on the kinetics of phenytoin
54. Carbamazepine intoxication caused by interaction with isoniazid
55. Isoniazid-induced carbamazepine toxicity and vice versa: A double drug interaction
56. Interaction between carbamazepine and antituberculosis agents
57. Acute liver failure caused by isoniazid in a child receiving carbamazepine
58. Isoniazid-induced valproic-acid toxicity, or vice versa
59. Interaction between isoniazid and valproate: A case of valproate overdosage
60. A clinical and pharmacokinetic case study of an interaction of levodopa and antituberculous therapy in Parkinson's disease
61. Interaction between isoniazid and theophylline
62. Lowering of theophylline clearance by isoniazid in slow and rapid acetylators
63. Theophylline-isoniazid interaction
64. Rifampicin-isoniazid and delayed elimination of theophylline: A case report
65. Effect of combined therapy of oral anti-tubercular agents on theophylline pharmacokinetics
66. Severe acetaminophen toxicity in a patient receiving isoniazid
67. Acetaminophen, isoniazid and hepatic toxicity
68. Hepatotoxicity associated with acetaminophen usage in patients receiving multiple drug therapy for tuberculosis
69. Acetaminophen hepatotoxicity: Potentiation by isoniazid
70. Inhibition and induction of cytochrome P4502E1-catalyzed oxidation by isoniazid in humans
71. Influence of polymorphic N-acetyl transferase phenotype on the inhibition and induction of acetaminophen bioactivation with long-term isoniazid
72. Interaction of isoniazid and warfarin
73. Potentiation of bishydroxycoumarin in dogs by isoniazid and p-aminosalicylic acid
74. Diazepam interaction with anti-tuberculosis drugs
75. Differential effect of isoniazid on triazolam oxidation and oxazepam conjugation
76. Effects of antacids on gastrointestinal absorption of isoniazid in rat and man
77. No interaction between H2 blockers and isoniazid
78. Effect of antacids in didanosine tablet on bioavailability of isoniazid
79. Pharmacokinetics of isoniazid under fasting conditions, with food, and with antacids
80. Effect of prednisolone and rifampicin on isoniazid metabolism in slow and rapid inactivators of isoniazid
81. Isoniazid-induced enflurane delfuorination in humans
82. Long term study of the effect of rifampicin and isoniazid on vitamin D metabolism
83. Effect of isoniazid on vitamin D metabolism and hepatic monooxygenase activity
84. Isoniazid and antidepressants: Is there cause for concern?
85. Coadministration of isoniazid and antidepressant drugs
86. Interaction between isoniazid and diverse vasodilators: Role of decreased cerebral GABA
87. Influence of various diets on the bioavailability of isoniazid
88. Isoniazid and reaction to cheese
89. Interactions of isoniazid with foods
90. Isoniazid interactions
91. Histamine poisoning after ingestion of spoiled raw tuna in a patient taking isoniazid
92. Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids
93. Loss of analgesic effect of morphine due to coadministration of rifampin
94. Rifampicin-aluminum antacid interaction
95. Interactions of chronic daily warfarin therapy and rifampin
96. Interactions of sodium warfarin and rifampin: Studies in man
97. The mechanism of the warfarin-rifampin drug interactions in humans
98. Influence of rifampicin on drug metabolism: Difference between hexobarbital and antipyrine
99. Age-dependent stereoselective increase in the oral clearance of hexobarbitone isomers caused by rifampicin
100. Reduced serum levels of clarithromycin in patients treated with multidrug regimens including rifampin or rifabutin for Mycobacterium avium-M intracellulare infection
101. Effect of rifampin on chloramphenicol levels
102. Interaction of chloramphenicol and rifampin
103. Drug interaction during multidrug regimens for treatment of leprosy
104. Influence of once-monthly rifampicin and daily clofazimine on the pharmacokinetics of dapsone in leprosy patients in Nigeria
105. Drug interactions in use of dapsone for Pneumocystis carinii prophylaxis
106. Possible implications of doxycycline-rifampin interaction for treatment of brucellosis
107. Interaction between fluconazole and rifampicin
108. Interaction of azoles with rifampicin, phenytoin, and carbamazepine: In vitro and clinical observations
109. Rifampin-fluoconazole interaction in critically ill patients
110. Itraconazole and antituberculosis drugs
111. Effect of rifampicin on the pharmacokinetics of itraconazole in normal volunteers and AIDS patients
112. Interaction of ketoconazole and rifampin and isoniazid
113. Serum fungistatic and fungicidal activity in volunteers receiving antifungal agents
114. Failure of ketoconazole treatment of Blastomyces dermatitis due to interaction of isoniazid and rifampin
115. Impact of rifampin on serum amiodarone concentrations in a patient with congenital heart disease
116. Interaction of bisoprolol with cimetidine and rifampicin
117. Clofibrate and enzymatic induction in man
118. Pharmacokinetic interactions with rifampin
119. Acute cardiac failure during treatment with digitoxin - An interaction with rifampicin
120. Interaction of rifampin and digitoxin
121. Rifampin and digoxin: Possible drug interaction in a dialysis patient
122. Digoxin-rifampin interaction
123. The influence of rifampin on quinidine and digoxin
124. Identification of the rabbit and human cytochromes P450 IIIA as the major enzymes involved in the N-demethylation of diltiazem
125. Effects of debrisoquine hydroxylation phenotype and enzyme induction with rifampin on diltiazem pharmacokinetics and pharmacodynamics
126. Attenuation of rifampicin-induced theophylline metabolism by diltiazem/rifampicin coadministration in healthy volunteers
127. The effect of enzyme induction on the metabolism of disopyramide in man
128. Enzyme induction: Rifampin-disopyramide interaction
129. A possible drug interaction between rifampicin and enalapril
130. Drug interaction between lorcainide and rifampicin
131. Effects of erythromycin or rifampin on losartan pharmacokinetics in healthy volunteers
132. Effect of rifampicin on metoprolol and antipyrine kinetics
133. Effect of rifampicin treatment on the kinetics of mexiletine
134. Pharmacology, electrophysiology and pharmacokinetics of mexiletine
135. A case of variant angina exacerbated by administration of rifampicin
136. Case report: Nifedipine-rifampin interaction attenuates the effect on blood pressure in a patient with essential hypertension
137. Rifampicin lowers plasma concentrations of propafenone and its antiarrhythmic effect
138. Enzyme induction in the elderly: Effect of rifampin on the pharmacokinetics and pharmacodynamics of propafenone
139. Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6
140. Induction of propanolol metabolism by rifampin
141. Quinidine-rifampin interaction
142. Quinidine-rifampin interaction
143. Interaction of tertatolol with rifampicin and ranitidine pharmacokinetics and antihypertensive activity
144. Influence of rifampin on tocainide pharmacokinetics in humans
145. Reduction of bioavailability of verapamil by rifampin
146. The influence of antituberculosis drugs on the plasma level of verapamil
147. Near-total reduction in verapamil bioavailability by rifampin: Electrocardiographic correlates
148. Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin
149. Gut wall metabolism of verapamil in older people: Effects of rifampicin-mediated enzyme induction
150. Rifampin drug interactions
151. Effects of rifabutin and rifampicin on the pharmacokinetics of ethinylestradiol and norethindrone
152. The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive
153. Changes in cortisol metabolism following rifampicin therapy
154. Rifampicin and cortisone replacement therapy
155. Rifampicin-induced adrenal crisis in Addisonian patients receiving corticosteroid replacement therapy
156. Rifampin-induced deterioration in steroid-dependent asthma
157. Interaction of rifampin and glucocorticoids: Adverse effects on renal allograft function
158. Rifampicin reduces effectiveness and bioavailability of prednisolone
159. Cyclosporin and antituberculosis therapy
160. The effects of rifampin on cyclosporine pharmacokinetics
161. Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction
162. Antituberculous drugs in kidney transplant recipients treated with cyclosporine
163. Drug interactions between cyclosporine and rifampicin, erythromycin and azoles in kidney recipients with opportunistic infections
164. Effect of short-term rifampin on stable cyclosporine concentrations
165. Effects of rifampin on cyclosporine disposition in kidney recipients with tuberculosis
166. Effects of rifampin on tacrolimus pharmacokinetics in healthy volunteers
167. Experience of tacrolimus-based immunosuppression in living-related liver transplantation complicated with graft tuberculosis: Interaction with rifampicin and side effects
168. Renal allograft dysfunction associated with rifampin-tacrolimus interaction
169. Effect of rifampin therapy on thyroid function tests in a hypothyroid patient on replacement L-thyroxine
170. Interaction between rifampin and levothyroxine
171. Rifampin-induced methadone withdrawal
172. Rifampicin and methadone withdrawal
173. The effect of antipyrine and rifampin on the metabolism of diazepam
174. Single dose pharmacokinetics and pharmacodynamics of oral oxazepam during concomitant administration of propanolol and labetolol
175. Rifampicin drastically reduces plasma concentrations and effects of oral midazolam
176. Comparative effects of rifampin and/or probenecid on the pharmacokinetics of temazepam and nitrazepam
177. Triazolam is ineffective in patients taking rifampin
178. Serum haloperidol levels of schizophrenics receiving treatment for tuberculosis
179. Effect of rifampin on the plasma concentration and the clinical effect of haloperidol concomitantly administered to schizophrenic patients
180. Drug interaction between rifampin and nortriptyline: A case report
181. Interaction of rifampin and nortriptyline
182. Rifampin-induced selective serotonin reuptake inhibitor withdrawal syndrome in a patient treated with sertraline
183. Concentrations and effects of zopiclone are greatly reduced by rifampicin
184. Rifampin reduces plasma concentrations and effects of zolpidem
185. The effect of rifampicin on sulphapyridine plasma concentrations following sulphasalazine administration
186. Interaction of rifampin and chlorpropamide
187. Serum glibenclamide in diabetic patients, and influence of food on the kinetics and effects of glibenclamide
188. Drug interaction: Rifampicin and glibenclamide
189. Interaction of rifampin and glyburide
190. Effect of rifampin on theophylline disposition
191. Effect of rifampin administration on theophylline pharmacokinetics in humans
192. Theophylline-rifampin interactions: Non-selective induction of theophylline metabolic pathways
193. Identification of rifampin-inducible P450 IIIA4 (CYP3A4) in human small bowel enterocytes
194. Complex interaction of rifampin and warfarin
195. Drug interaction between rifampicin and cotrimoxazole in patients with tuberculosis
196. Displacement of rifampicin bound to serum proteins by addition of levamisole
197. Inhibitory potency of quinolone antibacterial agents against cytochrome P-4501 A2 activity in vivo and in vitro
198. Quinolone antibacterial agents: Relationship between structure and in vitro inhibition of the human cytochrome P450 isoform CYP1A2
199. Ciprofloxacin pharamcokinetics after a standard or high-fat/high-calcium breakfast
200. Ofloxacin: Serum and skin blister fluid pharmacokinetics in the fasting and non-fasting state
201. Effects of food and sucralfate on a single oral dose of 500 milligrams of levofloxacin in healthy subjects
202. Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin
203. Effects of magnesium-aluminum hydroxide and calcium carbonate antacids on bioavailability of ofloxacin
204. Effects of antacids, ferrous sulfate, and ranitidine on absorption of DR-3355 in humans
205. Pharmacokinetics and bioavailability of ciprofloxacin and ofloxacin: Effect of food and antacid intake
206. The effect of sucralfate pretreatment on the pharmacokinetics of ciprofloxacin
207. Effect of sucralfate on absorption of norfloxacin and ofloxacin
208. Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers
209. Cations in the didanosine tablet reduce ciprofloxacin bioavailability
210. A multiple-dose pharmacokinetic interaction study between didanosine and ciprofloxacin in male subjects seropositive for HIV but asymptomatic
211. Effect of enteral feeding with ensure on oral bioavailabilities of ofloxacin and ciprofloxacin
212. Relative bioavailability in healthy volunteers of ciprofloxacin administered through a nasogastric tube with and without enteral feeding
213. Inhibition of drug metabolism by quinolone antibiotics
214. Impact of ciprofloxacin on theophylline clearance and steady-state concentrations in serum
215. Meta-analysis of quinolone-theophylline interactions
216. Interactions of fluoroquinolones with other drugs: Mechanisms, variability, clinical significance and management
217. Seizure with ciprofloxacin and theophylline combined therapy
218. Effect of levofloxacin on serum concentration of theophylline
219. Absence of a pharmacokinetic interaction between intravenous theophylline and orally administered levofloxacin
220. Inhibition of theophylline clearance by coadministered ofloxacin without alteration of theophylline effects
221. Ofloxacin and warfarin
222. Ciprofloxacin and warfarin interaction
223. Adverse reaction reporting of interaction between warfarin and fluoroquinolones
224. Enoxacin-warfarin interaction: Pharmacokinetic and stereochemical aspects
225. Norfloxacin does not alter warfarin's disposition or anticoagulant effect
226. Absence of an effect of levofloxacin on warfarin pharmacokinetics and anticoagulation in male volunteers
227. Norfloxacin-cyclosporine interaction
228. Norfloxacin interferes with cyclosporine disposition in pediatric patients undergoing renal transplantation
229. Possible interaction of ciprofloxacin with cyclosporin A
230. Synergistic nephrotoxicity due to ciprofloxacin and cyclosporine
231. Cyclosporine (cyclosporine A) pharmacokinetics in renal transplant patients receiving ciprofloxacin
232. Co-administration of ciprofloxacin and cyclosporine: Lack of evidence for a pharmacokinetic interaction
233. Investigation of a potential interaction of ciprofloxacin with cyclosporine in bone marrow transplant recipients
234. Effect of ciprofloxacin on cyclosporine pharmacokinetics
235. Levofloxacin does not alter cyclosporine disposition
236. Effect of ciprofloxacin on serum phenytoin concentrations in epileptic patients
237. Ciprofloxacin phenytoin interaction
238. Possible phenytoin-ciprofloxacin interaction
239. Effect of ciprofloxacin on the pharmacokinetics of multiple-dose phenytoin serum concentrations
240. Ciprofloxacin-phenytoin interaction
241. Interaction between phenytoin and ciprofloxacin
242. Effects of peptic-ulcer-healing drugs on the pharmacokinetics of new quinolone (OFL)
243. Pharmacokinetics of ofloxacin: An overview
244. The effects of cimetidine and probenecid on the pharmacokinetics of levofloxacin
245. Drug interactions with quinolones
246. Inhibitory effects of quinolone antibacterial agents on gamma-aminobutyric acid binding to receptor sites in rat brain membranes
247. Effect of the anti-inflammatory agent fenbufen on the quinolone-induced inhibition of γ-aminobutyric acid binding to rat brain membrances in vitro
248. The effects of quinolones and NSAIDs upon GABA-evoked currents recorded from rat dorsal root ganglion neurones
249. Interactions of quinolones with opioids and fenbufen, a nonsteroidal anti-inflammatory drug: Involvement of dopaminergic neurotransmission
250. Structure-epileptogenicity relationship of quinolones with special reference to their interaction with γ-aminobutyric acid receptor sites
251. Neuroexcitable effects of levofloxacin, a novel quinolone antibacterial, in concomitant use of non-steroidal anti-inflammatory drugs
252. Ciprofloxacin increases serum levels of theophylline
253. Drug interactions with fluoroquinolones
254. Interaction of ofloxacin and warfarin
255. Adverse neurological reactions in patients with multidrug-resistant pulmonary tuberculosis after co-administration of cycloserine and ofloxacin
256. Levofloxacin in the treatment of drug-resistant tuberculosis
257. Serum pharmacokinetics of antimycobacterial drugs in patients with multidrug-resistant tuberculosis during therapy
258. Neurological toxicity related to pefloxacin
259. Interaction between allopurinol and pyrazinamide
260. Effect of pyrazinamide on ciclosporin levels
261. Effect of aluminum hydroxide and glycopyrronium on the absorption of ethambutol and alcohol in man
262. Pharmacokinetics of ethambutol under fasting conditions, with food, and with antacids
263. Low antituberculosis drug concentrations in patients with AIDS
264. Reduced plasma concentrations of antituberculous drugs in patients with HIV infection
265. A pilot study of antituberculosis combinations comparing rifabutin with rifampicin in the treatment of HIV-associated tuberculosis
266. HIV disease severity does not influence rifabutin absorption
267. Pharmacokinetics of rifapentine in subjects seropositive for the human immunodeficiency virus: A phase I study
268. Oral bioavailability and pharmacokinetics of ciprofloxacin in patients with AIDS
269. Correlates of zidovudine phosphorylation with markers of HIV disease progression and drug toxicity
270. The effect of zidovudine dose on the formation of intracellular phosphorylated metabolites
271. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection
272. Phenobarbital inducible UDP-glucuronosyl transferase is responsible for glucuronidation of 3′-azido-3′- deoxythymidine: Characterization of the enzyme in human and rat liver microsomes
273. Pharmacokinetic interaction between rifampin and zidovudine
274. Evaluation of the antiviral effect of rifabutin in AIDS-related complex
275. The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin
276. Overview of in-vitro and in-vivo drug interaction studies of nelfinavir mesylate, a new HIV-protease inhibitor
277. Updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV-infected patients taking protease inhibitors or non-nucleoside reverse transcriprase inhibitors
278. Ritonavir enables combined therapy with rifampin and saquinavir
279. Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate
280. Pharmacokinetic study of the interaction between rifabutin and delavirdine mesylate in HIV-1 infected patients
281. Delavirdine and rifabutin: Pharmacokinetic evaluation in HIV-1 patients with concentration-targeting of detavirdine
282. Effect of tuberculosis therapy on nevirapine trough plasma concentrations
283. Increased incidence of peripheral neuropathy with co-administration of stavudine and isoniazid in HIV-infected individuals
284. High performance liquid chromatography determination of ethionamide and prothionamide in body fluids